immuno oncology frontiers world miami

  Immuno-Oncology Hub logo

Immuno-Hub: Solving clinical and bioprocessing challenges through innovation

Are you currently faced with challenges in cell-based manufacturing or getting a better patient response to your IO therapy? If so, our Immuno-Oncology Hub is where you need to be at Phacilitates Leaders Forum, taking you on a journey to explore innovation in these areas.

Phacilitate have bought together 6 technology innovators for a series of short 10 minute discussions focused on overcoming clinical and manufacturing challenges specific to IO biotechs.  Topics to be discussed in the hub include:

  • Precision medicine approaches
  • Biomarker solutions for patient response
  • Using genomics in your clinical trials
  • Next generation bioprocessing technologies


A guideline agenda can be found below: 

WEDNESDAY 24th January

Cell-based manufacturing innovation



4:00 pm Gather at the IO hub
4:10 pm Manufacturing challenges for GMP viral vector production: the importance of identifying experienced partners for the supply of critical raw materials
4:20 pm

Scale Up: How do you move from the research stage to the commercial stage

4:30 pm Merits of non-viral cellular engineering vs viral cellular engineering
4:40 pm How does the purity of the starting isolated cell population affect the efficacy/safety of the developed cell therapy treatment?
4:50 pm Regroup and feed back

5:00 pm

Drinks in the hub and networking
5:50 pm Phacilitate Yacht Party commences


Overcoming the patient response challenge: Precision Medicine and biomarker solutions


4:00 pm Gather at the IO hub
4:10 pm Challenges of heterogeneous solid tumors:  targeting broad spectrum of tumor biomarkers while also precision tailoring to the patient
NW Bio
4:20 pm

Interrogating the mechanisms of action - including individual gene marker expression levels - for immunotherapy agents using CLIA and CAP accredited assays

4:30 pm How do you identify which markers are relevant and how do you move these from translation into the clinic.
Myriad RBM
4:40 pm Regroup and feed back
4:50 pm Drinks in the hub and networking
5:50 pm Phacilitate Yacht Party commences


  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy